U.S. President Donald Trump on Monday said he thinks the United States will be able to reach a fair trade agreement with the European Union without imposing threatened tariffs on car imports, offering a potential lifeline to German carmakers.
Wall Street’s main indexes rose 1% on Monday as U.S. President Donald Trump eased his stance on trade with China, calming investor nerves after an intense feud between the world’s top two economies last week sent stocks tumbling.
Oil prices edged lower on Monday on the outlook for increased supply of Iranian crude after France’s president lifted hopes for a deal between Washington and Tehran, but losses were limited by growing hopes that the United States and China could make a deal to end their trade war.
An Oklahoma judge on Monday will decide whether Johnson & Johnson should be held liable in a $17 billion lawsuit alleging the drugmaker’s marketing practices fueled the opioid epidemic by flooding the market with painkillers.
Summer is coming to an end. The colder seasons are approaching. And if you enjoy downhill skiing, the three-month chart of the North American Marijuana Index probably looks like a lot fun…
But for pot stock investors, this isn’t the type of slope we want to see.
The index has fallen 9.7% so far in the month of August. But since May 23, it’s down 28.3%.
The sector has been rocked by scandal, then kicked while it was down by a series of earnings misses from Canadian producers in recent weeks.
But there’s another specter besides earnings haunting the cannabis sector…
Fed Up With the …read more […]
U.S. President Donald Trump on Monday predicted a trade deal with China after positive gestures by Beijing, calming global markets that have been roiled by new tariffs from the world’s two largest economies.
A global gauge of equities rose on Monday and the dollar recovered from earlier losses as U.S. President Donald Trump said Chinese officials had contacted Washington about resuming trade negotiations, after signs of escalation in the U.S.-China trade dispute had roiled markets earlier in the day.
New orders for key U.S.-made capital goods rose modestly in July while shipments fell by the most in nearly three years, pointing to continued weakness in business investment and a slowdown in economic growth early in the third quarter.
Wall Street’s main indexes rose on Monday as U.S. President Donald Trump eased his stance on trade with China, calming investor nerves after an intense feud between the world’s top two economies last week sent stocks tumbling.
Oil prices steadied on Monday after France’s president lifted hopes for a deal between the United States and Iran, while optimism for easing U.S.-China trade tensions supported prices.
Japanese Prime Minister Shinzo Abe said on Monday stable relations between the United States and China are “very important” not just for these economies, but for the sake of the global economy.
Many people think that economic inequality is a huge problem in America, but that’s not true.
Today, Alexander Green explains how inequality shows that our free market system is working.
In my last column, I argued that – contrary to many voices on the far left and far right – capitalism doesn’t need to be reformed.
Those who claim that it does generally cite the same reason: economic inequality.
In particular, many politicians hope to garner enough votes to gain (or regain) elected office by promising to fix the problem with massive income redistribution.
Some agree, arguing that it is wrong for some Americans to …read more […]
Kraft Heinz Co’s newly-appointed chief executive officer replaced finance chief David Knopf on Monday in what he said was a strategic decision, naming the more “seasoned” Paulo Basilio, after the company was forced to restate three years of results.
U.S. President Donald Trump said on Monday he was confident that China was sincere about wanting a trade deal with the United States because it had taken “a very large hit” in recent months.
Amgen Inc will buy Celgene Corp’s psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene by the end of the year.
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
